Expanded the U.S. active device base to approximately 4,500 TearLab Osmolarity Systems Staffed 97% of U.S. field sales positions
Reduced operating expenses by 29% and operating loss by 46% compared to first quarter 2016
Reduced cash burn to $2.4 million, from $6.6 million in first quarter 2016
Achieved initial CE Marking for next generation platform, providing regulatory clearance in the European Union and European Free Trade Association member countries Received regulatory approval for the TearLab Osmolarity System in Brazil, well ahead of anticipated schedule
most important.cash balance of $13.0 million as of March 31, 2017.
“In addition, we are very pleased that nearly all of our U.S. field sales positions were filled, and we have seen the positive impact of having a full sales team with a stronger start to our second quarter in both revenue and placements than what we experienced in early Q1 2017.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.